Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > JDRF-funded researcher wins prestigious award at international diabetes conference
Professor Maike Sander, a JDRF-funded researcher, has won the prestigious Albert Renold Prize at the recent EASD (European Association for the Study of Diabetes) conference.
Professor Sander said: “It’s a true honour to be recognised with this prize. I have been fortunate to work with outstanding trainees who really deserve the credit. Thank you also to all collaborators for their creativity and generous contributions.”
The prize was awarded at the latest EASD conference, which saw around 12,000 diabetes researchers, advocates and healthcare workers congregate in Sweden to share brand new developments in the field.
This coveted prize is awarded each year to one researcher for their ‘outstanding achievement’ in studying a group of cells called pancreatic islets, where insulin-producing beta cells are found.
Out of the 16 prizes awarded in total, 13 of those have gone to researchers who were funded by JDRF at some point in their career. This shows that JDRF consistently funds research that is internationally recognised as being the very best.
Professor Sander is currently based in California, but will soon move to Berlin, Germany. Her team grows beta cells from human stem cells, and she gave an update on their projects in her Award Lecture at EASD.
Lab-grown beta cells don’t function as well as real human beta cells, meaning they don’t release enough insulin in response to glucose. Professor Sander delved into their genetics to understand why.
The researchers used stem cells to grow pancreatic islets containing beta cells and compared them to human pancreatic islets from donors. They discovered that they were making an immature version of human beta cells found in fetuses, known as fetal beta cells. So, the next step was to figure out how to get these cells to mature into functioning adult beta cells.
Professor Sander’s team also noticed that stress pathways were more active in beta cells from donors. The research team thinks that mild stress may help beta cells mature. Their next task is to test whether this works, and we look forward to hearing their results.
Pancreatic islets receive a large supply of blood to provide them with the nutrients and oxygen they need. In contrast, beta cells in the lab are made without blood vessels. So, Professor Sander’s team worked with bioengineers to grow pancreatic islets alongside blood vessels on a chip.
When they tested these beta cells’ response to glucose, they found they functioned better than islets they had grown without a blood supply. This demonstrates to other researchers the need to grow beta cells with connecting blood vessels.
The lab’s next project will involve taking samples of blood and stem cells from people with type 1 and growing these into beta cells and immune cells in the lab. They will use these to mimic the immune attack that occurs in type 1 to better understand how it could be prevented and treated.
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.
Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.